SFI Health Partners with Curasense for Equazen® in Belgium and Netherlands

SFI HealthTM EMEA has signed an exclusive licensing agreement with Curasense BV to distribute the Equazen® food supplements in the Netherlands and Belgium. This partnership, announced on September 25, 2025, enables Curasense to market products containing a clinically researched blend of essential fatty acids, designed to support cognitive health.

Curasense, based in Belgium, will hold the exclusive rights to promote, distribute, and sell Equazen® products within these two countries following a transition period from SFI HealthTM’s previous licensee. The agreement is strategically significant considering the presence of over 6,500 pharmacies in Belgium and the Netherlands, alongside approximately 2,800 health stores across the region.

The expansion into these markets aligns with the rising consumer demand for brain health supplements. The sector is projected to grow at a compound annual growth rate (CAGR) of 12.5% in Europe between 2023 and 2030, driven by an increasing focus on cognitive wellness and mental health.

Matthew Brabazon, General Manager of SFI HealthTM EMEA, expressed optimism about the collaboration. He stated, “We are very pleased to collaborate with Curasense, a company with extensive experience in the healthcare sector and a strong reputation among healthcare professionals and consumers. This partnership marks an important step in strengthening the Equazen® brand.”

Similarly, Jelle D’Helft, CEO of Curasense, emphasized the significance of this agreement for their mission to deliver evidence-based health solutions. He noted, “Equazen®’s clinically supported formulations align closely with our vision and reflect our ambition to bridge conventional and complementary medicine.”

Equazen® has been a recognized name in the nutraceutical industry, with its products designed to nourish and enhance brain function across all life stages. The brand has been clinically proven for over 20 years to support learning capabilities, concentration, and healthy brain development.

Currently, Equazen® is marketed in various EMEA markets, including Spain, Portugal, the United Kingdom, and Poland, with plans to expand further. This collaboration is expected to enhance the brand’s visibility and market share in Belgium and the Netherlands, allowing it to meet the growing demand for cognitive health solutions.

With a solid foundation built on scientific research, both SFI HealthTM and Curasense are committed to providing high-quality, effective health products. SFI HealthTM, headquartered in Australia, operates globally, focusing on natural healthcare solutions that combine rigorous research with naturally sourced ingredients.

Curasense, with over 20 years in the healthcare sector, prides itself on its dedication to quality and compliance with European regulations. The company aims to make advanced health solutions available across Europe and beyond, emphasizing their commitment to bridging the gap between traditional and complementary medicine.

This partnership not only strengthens the Equazen® brand’s position in the nutraceutical market but also reflects a growing trend towards prioritizing mental health and cognitive function among consumers. As such, it represents a significant advancement in the health and wellness sector.